Houston sustainable energy company to be acquired by industry giant for $4.1B

big buyout

Houston-based Archaea Energy's RNG facilities capture waste emissions and convert them into low-carbon fuel. Photo via archaeaenergy.com

BP’s proposed $4.1 billion acquisition of Houston-based Archaea Energy promises to dramatically boost the energy giant’s presence in the biogas market.

Publicly traded Archaea is one of the largest producers of renewable natural gas, or RNG, in the U.S. Its RNG facilities capture waste emissions and convert them into low-carbon fuel. Biogas is produced through the conversion of organic matter like animal manure, trash, plant material, food waste, and sewage.

Through the cash-and-debt deal, BP will gain ownership of 50 RNG and landfill gas-to-energy facilities across the U.S. Once the deal is wrapped up, BP anticipates a 50 percent increase in biogas volumes.

Archaea's development pipeline of more than 80 projects holds the potential for a fivefold increase in RNG volumes at BP by 2030. The pipeline includes 40 RNG projects that Archaea plans to develop with Republic Services, a solid waste disposal company based in Phoenix. Republic Services is a rival of Houston-based Waste Management.

BP expects Archaea to double its biogas-driven EBITDA to about $2 billion within the next eight years. Allied Market Research predicts the global market for waste-derived biogas will jump from $52.9 billion in 2020 to $126.2 by 2030.

The Archaea acquisition is set to close later this year. Once the deal is completed, Archaea will operate as subsidiary of BP, whose U.S. headquarters is in Houston. Archaea relocated its headquarters from Pittsburgh to Houston last year.

“Archaea was founded with a mission to build the world’s leading RNG development company to reduce global emissions and make multigenerational sustainability impacts,” Nick Stork, co-founder and CEO of Archaea, says in a news release. “In a very short period of time, we have rapidly become a leading RNG platform in the U.S., and [the BP acquisition] will further enable this business to realize its full potential.”

BP notes that the demand for biogas is rising thanks to the growth of renewable hydrogen, electric-vehicle charging, and other emerging segments of the energy sector.

“Our biogas team is already one of the leading suppliers of renewable natural gas in North America,” Dave Lawler, chairman and president of BP America, says in a news release. “This deal accelerates our ability to deliver cleaner energy, generate significant earnings in a fast-growing sector, and help reduce emissions. This could help BP take a significant stride toward our net-zero ambition.”

BP America employs nearly 4,000 full-time workers in Houston.

More than half of non-Texans think the Lone Star State is great for business. Photo via Getty Images

Here's what non-Texans think about the Lone Star State's business economy

yeehaw

As Houston and the rest of Texas continue to welcome out-of-state businesses, there’s some affirming news from a new poll. More than half of non-Texans believe the Lone Star State is a good place to launch a business.

The survey, conducted earlier this summer by Austin-based Crosswinds Media & Public Relations and Asbury Park, New Jersey-based Rasmussen Reports, a conservative-leaning polling company, found 53 percent of non-Texans had a positive perception of Texas as a place to do business. Only 23 percent of adults outside Texas had a “bad” or “very bad” view of the state’s business environment, while 24 percent said they were unsure.

The survey questioned 845 American adults who don’t live in Texas.

Thomas Graham, president and CEO of Crosswinds, says the survey results demonstrate that “the brand of the Lone Star State remains strong.”

In recent years, a number of out-of-state companies have been lured by that brand as well as the business climate in Houston. Notable examples include Hewlett Packard Enterprise, NRG Energy, and Axiom Space.

Just this year, several companies based outside Texas have revealed headquarters moves to the Houston area. Among them are:

  • Archaea Energy, which was based in Pittsburgh. The company produces renewable natural gas.
  • CDI Engineering Solutions, which was based in Philadelphia. The company provides engineering and architecture services.
  • DarkPulse, which was based in New York City. The company develops fiber-sensor technology.
  • Noodoe EV, which was based in Irvine, California. The company’s cloud-based platform manages charging stations for electric vehicles.

Jennifer Chang, CEO of Noodoe, says her company relocated its headquarters from Southern California to Texas to take advantage of Houston’s central location.

“Houston has the port and airport capacity we need to efficiently meet the unprecedented demand for EV charging stations,” Chang said in a January news release. “Houston has long been the Energy Capital of the World, mostly because of oil and gas extraction. Noodoe will help the city continue its energy legacy, only this time without fossil fuels.”

The poll from Crosswinds and Rasmussen was completed around the same time that CNBC released its ranking of the best states for doing business. Texas landed in fifth place, down one notch from its perch in CNBC’s 2021 study. A day later, CNBC put out a list of the worst states to live, with Texas appearing at No. 2 behind Arizona.

CNBC notes that skilled workers are flooding Texas, even though the quality of life here raises questions. The new arrivals “are finding limited childcare options, a stressed health care system with the highest rate of uninsured, new curbs on voting rights, and few protections against discrimination,” the cable TV network declares.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings